title: Experience of bevacizumab in a patient with colorectal cancer after renal transplantation.
abstract: Bevacizumab is a drug that is widely used for the first-line treatment of metastatic colorectal cancer (mCRC). Bevacizumab neutralizes vascular endothelial growth factor and can lead to proteinuria and renal damage. In this case, experience on full dose short-time treatment of bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic renal failure has been shared. The patients were diagnosed with mCRC 7 months ago. The patient had multiple liver metastases at the time of the diagnosis. He had a history of renal transplantation 2 years ago because of renal failure, and he had been under immunosuppressive treatment for this reason. 5-fluorouracil-leucovorin-irinotecan -bevacizumab regimen was begun for the treatment of mCRC. The dose of bevacizumab was 5 mg/kg/day for 14 days. There was 2.5 g/day of proteinuria at the start of the treatment. However, renal dysfunction progressed, and proteinuria increased to 4 g/day in the 3rd month of treatment. In this case, the experience of using bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic failure has been presented.
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Fatma Yalcin
authors.initials: FY
authors.lastname: Müsri
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.forename: Melek Karakurt
authors.initials: MK
authors.lastname: Eryılmaz
authors.forename: Derya Kıvrak
authors.initials: DK
authors.lastname: Salim
authors.forename: Hasan Şenol
authors.initials: HŞ
authors.lastname: Coşkun
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D016030:Kidney Transplantation / Q000009:adverse effects*; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D011379:Prognosis; D051437:Renal Insufficiency / Q000209:etiology / Q000601:surgery*
chemical_list: D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin